Brigitte Royer-Pokora

List of Publications by Year
in descending order

52 papers	3,865 citations	218677 26 h-index	182427 51 g-index
54 all docs	54 docs citations	54 times ranked	4508 citing authors

#	Article	IF	Citations
1	Cloning the gene for an inherited human disorderâ€"chronic granulomatous diseaseâ€"on the basis of its chromosomal location. Nature, 1986, 322, 32-38.	27.8	833
2	Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell, 1991, 67, 1059-1074.	28.9	810
3	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nature Genetics, 2014, 46, 107-115.	21.4	410
4	Transformation parameters in chicken fibroblasts transformed by AEV and MC29 avian leukemia viruses. Cell, 1978, 13, 751-760.	28.9	144
5	Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Research, 2009, 69, 2996-3003.	0.9	139
6	Twentyâ€four new cases of WT1 germline mutations and review of the literature: Genotype/phenotype correlations for Wilms tumor development. American Journal of Medical Genetics Part A, 2004, 127A, 249-257.	2.4	135
7	Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney International, 1998, 53, 1594-1600.	5.2	129
8	BASP1 Is a Transcriptional Cosuppressor for the Wilms' Tumor Suppressor Protein WT1. Molecular and Cellular Biology, 2004, 24, 537-549.	2.3	120
9	Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1. Genes and Development, 2001, 15, 328-339.	5.9	76
10	Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Human Molecular Genetics, 2010, 19, 1651-1668.	2.9	66
11	Comparative performance analysis of human iPSC-derived and primary neural progenitor cells (NPC) grown as neurospheres in vitro. Stem Cell Research, 2017, 25, 72-82.	0.7	61
12	Pathological assessment of mismatch repair gene variants in Lynch syndrome: Past, present, and future. Human Mutation, 2012, 33, 1617-1625.	2.5	60
13	Genetics of pediatric renal tumors. Pediatric Nephrology, 2013, 28, 13-23.	1.7	59
14	Isolation of UV-resistant revertants from a xeroderma pigmentosum complementation group A cell line. Nature, 1984, 311, 390-392.	27.8	57
15	Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 825-831.	4.5	52
16	Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherinâ€associated protein Î²1 gene CTNNB1 for patients with Wilms tumors. Cancer, 2008, 113, 1080-1089.	4.1	50
17	Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clinical Cancer Research, 2003, 9, 2005-14.	7.0	49
18	Direct pulsed field gel electrophoresis of Wilms' tumors shows that dna deletions in 11 p 13 are rare. Genes Chromosomes and Cancer, 1991, 3, 89-100.	2.8	44

#	Article	IF	Citations
19	Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes and Cancer, 2007, 46, 1119-1128.	2.8	43
20	Exon skipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms' tumor and severe genital malformations. Human Genetics, 1993, 91, 599-604.	3.8	42
21	Reduction of the tumorigenic potential of human retinoblastoma cell lines byTFF1overexpression involves p53/caspase signaling and miR-18a regulation. International Journal of Cancer, 2017, 141, 549-560.	5.1	38
22	Mutant avian erythroblastosis virus with restricted target cell specificity. Nature, 1979, 282, 750-752.	27.8	33
23	Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2006, 165, 51-63.	1.0	30
24	Fusion of H4/D10S170 to PDGFRÎ² in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Annals of Hematology, 2007, 86, 353-354.	1.8	28
25	Bilateral Wilms Tumor in a Boy with Severe Hypospadias and Cryptorchidism Due to a Heterozygous Mutation in the WT1 Gene. Pediatric Research, 1999, 45, 187-190.	2.3	28
26	Structural chromosome abnormalities, increased DNA strand breaks and DNA strand break repair deficiency in dermal fibroblasts from old female human donors. Aging, 2015, 7, 110-122.	3.1	27
27	Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate, 2002, 50, 135-144.	2.3	25
28	Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. Journal of Medical Genetics, 2007, 44, 393-396.	3.2	25
29	Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. Familial Cancer, 2011, 10, 273-284.	1.9	24
30	Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2. Journal of Cancer Research and Clinical Oncology, 2010, 136, 123-134.	2.5	22
31	Analysis of native WT1 protein from frozen human kidney and Wilms' tumors. Oncogene, 1999, 18, 2533-2536.	5.9	21
32	Slow progressive FSGS associated with an F392L WT1 mutation. Pediatric Nephrology, 2004, 19, 353-356.	1.7	20
33	Wilms' tumor-specific methylation pattern in 11p13 detected by PFGE. Genes Chromosomes and Cancer, 1992, 5, 132-140.	2.8	18
34	Clinical, cytogenetic, and molecular observations in a patient with Pallisterâ€Killianâ€s syndrome with an unusual karyotype. American Journal of Medical Genetics Part A, 2003, 123A, 296-300.	2.4	18
35	Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. Leukemia Research, 2004, 28, 171-177.	0.8	15
36	Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation. Human Molecular Genetics, 2014, 23, 3958-3974.	2.9	15

#	Article	IF	Citations
37	A novel C8orf37 splice mutation and genotype-phenotype correlation for cone-rod dystrophy. Ophthalmic Genetics, 2016, 37, 294-300.	1.2	14
38	Chemotherapy and terminal skeletal muscle differentiation in <scp>WT</scp>1â€mutant Wilms tumors. Cancer Medicine, 2018, 7, 1359-1368.	2.8	11
39	Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2006, 167, 66-69.	1.0	10
40	Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE, 2016, 11, e0155561.	2.5	10
41	Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations. Cancers, 2021, 13, 60.	3.7	10
42	Unbalanced cryptic translocation der(14)t(9;14)(q34.3;q32.33) identified by subtelomeric FISH. Clinical Dysmorphology, 2003, 12, 261-265.	0.3	7
43	PromoterÂ1 ofLMO2, a master gene for hematopoiesis, is regulated by the erythroid specific transcription factor GATA1. Gene Function & Disease, 2000, 1, 87-94.	0.3	6
44	A novel post-transcriptional splicing form of the acute T cell leukemia proto-oncogeneLmo2. Science in China Series C: Life Sciences, 2001, 44, 561-569.	1.3	6
45	Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatric Blood and Cancer, 2022, 69, e29401.	1.5	6
46	Wilms Tumors Arising at Young Age: A Genetic Basis to Distinguish Subgroups for Individualized Therapy. Journal of Clinical Oncology, 2011, 29, e485-e486.	1.6	5
47	A novel inverted 17p13.3 microduplication disrupting PAFAH1B1 (LIS1) in a girl with syndromic lissencephaly. American Journal of Medical Genetics, Part A, 2013, 161, 1453-1458.	1.2	5
48	WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1. Journal of Pediatric Hematology/Oncology, 2021, 43, e180-e183.	0.6	4
49	Evaluation of Chromosome 11p Imbalances in Aniridia and Wilms Tumor Patients. American Journal of Medical Genetics, Part A, 2013, 161, 958-964.	1.2	2
50	Adjuvant chemotherapy (ACT) in stage II colon cancer (CC) in patients with Lynch syndrome.. Journal of Clinical Oncology, 2012, 30, 3550-3550.	1.6	2
51	A subtelomeric cryptic unbalanced translocation der (1)t(1;18)(q44;q23) in a severely retarded girl: similarities and differences to the deletion 1q42/43-ter syndrome. Gene Function & Disease, 2001, 2, 165-170.	0.3	1
52	Wilms and Rhabdoid Tumors of the Kidney. , 0, , 231-243.		0